Empagliflozin/Linagliptin and Ranolazine Interaction

Understanding the Empagliflozin/Linagliptin and Ranolazine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Empagliflozin/Linagliptin belongs to the SGLT2 / DPP-4 Combination class and Ranolazine belongs to the Late Sodium Current Inhibitor (Antianginal) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Ranolazine prevents the kidneys from properly removing metformin from your system, leading to higher amounts of the drug in your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Empagliflozin/Linagliptin has 11 total documented interactions on file in this dataset, and Ranolazine has 31. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Talk to your doctor about monitoring your blood sugar and checking for signs of too much metformin in your system. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Empagliflozin/Linagliptin or Ranolazine based on a web page, speak with your prescriber or pharmacist before making any change.